阿德福韦酯治疗失代偿期乙型肝炎肝硬化患者的临床治疗及其疗效分析

目的:对阿德福韦酯治疗失代偿期乙型肝炎肝硬化患者的临床治疗和疗效进行观察分析。方法:对116例失代偿期乙型肝炎肝硬化患者进行分组,将其随机分为实验组(治疗组)和对照组,其中对实验组和对照组分别采用阿德福韦酯治疗和拉米夫定治疗,并对实验组和对照组的临床症状的改善情况进行对比,同时比较肝功能治疗前后的变化情况和血清HBVDNA治疗后的转阴率。结果:与对照组相比,治疗组的临床症状有明显的改善,且在10～12个月复查血清HBVDNA,得出转阴率得到大幅度改善。结论:采用阿德福韦酯对失代偿期乙型肝炎肝硬化的治疗比采用拉米夫定治疗效果更好。

Adefovir Dipivoxil Therapy in Patients with Decompensated Cirrhosis and the Clinical Efficacy of Treatment

Objective:Of adefovir dipivoxil in patients with decompensated liver cirrhosis and clinical efficacy of observation and analysis.Method:In 116 patients with decompensated cirrhosis group were randomly divided into experimental group(treatment group) and control group,in which the experimental and control groups were used to adefovir dipivoxil and Lamy telbivudine treatment,and the experimental group and control group,improvement in clinical symptoms were compared at the same time more liver function changes before and after treatment and after treatment serum HBV DNA negative conversion rate.Rresults:Compared with the control group,treatment group,clinical symptoms improved significantly,and in 10 to 12 months later the serum HBV DNA,obtained a significant improvement in negative rate.Conclusions:Adefovir dipivoxil for decompensated liver cirrhosis treated with lamivudine treatment is better than.